Advertisement

Topics

Press Release: Novartis: Sandoz receives approval in Europe for Rixathon(R) (biosimilar rituximab) to treat blood cancers and immunological diseases

01:46 EDT 19 Jun 2017 | FinanzNachrichten

Novartis International AG / Sandoz receives approval in Europe for Rixathon(R) (biosimilar rituximab) to treat blood cancers and immunological diseases . Processed and transmitted by Nasdaq Corpor...

Original Article: Press Release: Novartis: Sandoz receives approval in Europe for Rixathon(R) (biosimilar rituximab) to treat blood cancers and immunological diseases

NEXT ARTICLE

More From BioPortfolio on "Press Release: Novartis: Sandoz receives approval in Europe for Rixathon(R) (biosimilar rituximab) to treat blood cancers and immunological diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...